rs727479 — CYP19A1

Intronic eQTL variant in the aromatase gene CYP19A1; the minor C allele is the strongest common genetic determinant of lower circulating estradiol in postmenopausal women, acting through altered aromatase expression in peripheral tissues.

See your personal result for CYP19A1

Upload your DNA data to find out which genotype you carry and what it means for you.

Upload your DNA data

Works with 23andMe, AncestryDNA, and other DNA test exports. Results in under 60 seconds.

The Estrogen Dial — How rs727479 Controls Your Aromatase Output

Estrogen doesn't come only from the ovaries. After menopause — and throughout life in men and premenopausal women — a substantial fraction of circulating estradiol is made locally in adipose tissue, bone, brain, and liver through the action of aromatase11 aromatase
the enzyme encoded by CYP19A1 that converts androgens such as testosterone and androstenedione into estrogens. The amount of aromatase produced in peripheral tissues is controlled partly by which alleles you carry at regulatory sites within CYP19A1. rs727479, a variant in intron 4 of the gene, has emerged through multiple independent genome-wide association studies as the single best common genetic predictor of circulating estradiol levels — particularly in postmenopausal women, when peripheral aromatase becomes the dominant source of estrogen.

The Mechanism

rs727479 is located at chr15:51242349 (GRCh38), within an intron of CYP19A1 on the minus strand of chromosome 15. It does not alter the aromatase protein sequence; instead, it influences gene expression. Glubb et al. demonstrated that the variant alters binding motifs for four transcription factors and lies within a putative regulatory element22 Glubb et al. demonstrated that the variant alters binding motifs for four transcription factors and lies within a putative regulatory element
Glubb DM et al. The Association of CYP19A1 Variation with Circulating Estradiol and Aromatase Inhibitor Outcome. Front Pharmacol 2017, providing a direct mechanistic explanation for why C-allele carriers produce less aromatase mRNA in peripheral tissues. Because CYP19A1 is regulated by tissue-specific promoters, the effect is most pronounced in tissues that rely on intronic regulatory elements — including adipose and bone — where aromatase expression in postmenopausal women accounts for the majority of total-body estrogen synthesis.

The C allele at this position is the minor allele globally (~29%), with the common A allele carried by ~71% of people. In genome files, alleles are reported on the plus strand: A is the common allele associated with normal aromatase expression, and C is the minor allele associated with lower expression and lower estradiol.

The Evidence

Circulating estradiol. Prescott et al. conducted a genome-wide association study in ~1,600 postmenopausal women not using hormone therapy33 Prescott et al. conducted a genome-wide association study in ~1,600 postmenopausal women not using hormone therapy
Prescott J et al. Genome-wide association study of circulating estradiol, testosterone, and sex hormone-binding globulin in postmenopausal women. PLoS One 2012. rs727479 was the top signal at the CYP19A1 locus for circulating estradiol (β = −0.107, p = 5.11×10⁻⁷), with 34 additional correlated SNPs in the region reaching p < 10⁻⁵. Glubb et al. subsequently synthesized data across four large studies totalling more than 10,000 women44 Glubb et al. subsequently synthesized data across four large studies totalling more than 10,000 women
Glubb DM et al. Front Pharmacol 2017 and identified rs727479 as the variant that best captures the estradiol signal across the locus, with effect sizes of 5–10.7% lower estradiol per C allele (p = 1.3×10⁻¹⁰ in the largest dataset). All other associated CYP19A1 variants were in linkage disequilibrium with rs727479 (r² = 0.10–0.51), confirming a single genetic signal.

Bone mineral density. Estradiol is a key suppressor of osteoclast-driven bone resorption. Eriksson et al. used Mendelian randomization in 11,097 men to establish a causal link between CYP19A1-driven circulating estradiol and lumbar spine bone mineral density55 Eriksson et al. used Mendelian randomization in 11,097 men to establish a causal link between CYP19A1-driven circulating estradiol and lumbar spine bone mineral density
Ruth KS et al. Genetic Determinants of Circulating Estrogen Levels and Evidence of a Causal Effect of Estradiol on Bone Density in Men. J Clin Endocrinol Metab 2018: each 1 pg/mL genetically higher estradiol was associated with a 0.048 SD increase in lumbar spine BMD. This finding is consistent with the known biology of estrogen deficiency and osteoporosis, and extends it to genetic variation in estrogen biosynthesis.

Endometrial cancer. Thompson et al. fine-mapped the CYP19A1 locus and applied Mendelian randomization to establish that the estradiol-raising allele causally increases endometrial cancer risk66 Thompson et al. fine-mapped the CYP19A1 locus and applied Mendelian randomization to establish that the estradiol-raising allele causally increases endometrial cancer risk
Thompson DJ et al. CYP19A1 fine-mapping and Mendelian randomization: estradiol is causal for endometrial cancer. Endocr Relat Cancer 2016. rs727479 was among the lead variants at the locus; the C allele (lower estradiol) corresponds to lower endometrial cancer risk.

Late-life depression. Ancelin et al. followed 1,007 adults aged 65 or older and found that CYP19A1 estradiol-modulating variants were associated with depression risk in a sex-specific pattern77 Ancelin et al. followed 1,007 adults aged 65 or older and found that CYP19A1 estradiol-modulating variants were associated with depression risk in a sex-specific pattern
Ancelin ML et al. Aromatase (CYP19A1) gene variants, sex steroid levels, and late-life depression. Depress Anxiety 2020. In postmenopausal women without prior depression, lower-estradiol genotypes increased incident depression risk; in women with prior depression, some variants were protective. This reflects the known role of estrogen in modulating serotonergic and noradrenergic neurotransmitter systems.

Aromatase inhibitor response. Because rs727479 predicts baseline aromatase output, individuals with higher baseline aromatase expression (AA genotype) require more complete suppression to achieve the same absolute estradiol reduction during aromatase inhibitor therapy. The clinical significance for treatment outcomes remains an active area of investigation.

Practical Actions

Carriers of the CC genotype produce meaningfully less estrogen through peripheral aromatase. In postmenopausal women, this translates to clinically lower serum estradiol, which has downstream effects on bone density, cardiovascular risk, mood, and endometrial cancer risk (reduced in CC carriers). Monitoring bone density and being aware of estrogen-deficiency-related symptoms is specifically warranted.

For women undergoing aromatase inhibitor therapy (letrozole, anastrozole), CC carriers start with already-low peripheral estrogen; their symptoms of estrogen deficiency during AI therapy may be more pronounced. Conversely, AA homozygotes (higher aromatase output) may require confirmation that AI therapy is achieving adequate estradiol suppression.

For men with prostate cancer, the C-allele direction (lower aromatase-mediated estrogen synthesis) translates to higher androgen-to-estrogen ratios, which may influence hormone-sensitive tumor biology and response to androgen deprivation therapy.

Interactions

rs727479 sits within a CYP19A1 haplotype block alongside rs4775936 (I.6 promoter variant associated with BMD and AI response), rs2414096 (intron 4 variant associated with PCOS and androgen levels), and rs2414095 (intron 3 variant). These variants are in linkage disequilibrium (r² = 0.10–0.51) and their combined haplotype consistently shows stronger associations than any single SNP alone. In downstream signaling, the estrogen produced by aromatase must bind to estrogen receptors encoded by ESR1 (see related variant rs9340799) — so the combination of altered aromatase output (CYP19A1) and altered receptor sensitivity (ESR1) can amplify or dampen the functional consequences.

Drug Interactions

letrozole reduced_efficacy literature
anastrozole reduced_efficacy literature

Nutrient Interactions

calcium increased_need
vitamin D increased_need

Genotype Interpretations

What each possible genotype means for this variant.

AA Normal Aromatase Output Normal

Common genotype — normal peripheral aromatase expression and circulating estradiol

You carry two copies of the common A allele at rs727479. This genotype is associated with typical aromatase expression in peripheral tissues (adipose, bone, brain) and normal circulating estradiol levels. About 49% of people globally share this genotype, making it the most common. The A allele is the major allele at this locus in every population studied. Your aromatase output in peripheral tissues follows the baseline pattern established in large-scale GWAS studies of circulating estradiol in postmenopausal women.

AC Reduced Aromatase Output Intermediate

One copy of the C allele — modestly lower peripheral aromatase expression and estradiol

The C allele at rs727479 alters binding motifs for four transcription factors within a putative regulatory element inside CYP19A1, reducing aromatase mRNA output in peripheral tissues. With one copy, you sit between the AA (normal) and CC (lowest) genotypes on the estradiol continuum. In the Prescott 2012 GWAS (N=1,583 postmenopausal women), each C allele was associated with a β = −0.107 reduction in log-transformed estradiol (p=5.11×10⁻⁷), representing roughly a 10% reduction per allele.

Practically, the AC genotype is unlikely to require specific clinical intervention in premenopausal women, where ovarian estrogen production dominates. The effect becomes more relevant after menopause, during aromatase inhibitor therapy, or in men where peripheral aromatase is the primary source of estradiol.

The lower-estradiol direction of this variant also has a protective signal for endometrial cancer (Thompson et al. 2016 Mendelian randomization) and a potential adverse signal for bone density and mood (Mendelian randomization data from Ruth 2018 and observational data from Ancelin 2020).

CC Low Aromatase Output Decreased

Two copies of the C allele — lowest common level of peripheral aromatase expression and circulating estradiol

The CC genotype carries two copies of the C allele, which reduces binding affinity for multiple transcription factors in a regulatory element within CYP19A1 intron 4. Lower transcription factor binding leads to reduced aromatase mRNA and protein output in peripheral tissues — particularly adipose tissue and bone — which are the dominant sites of estrogen synthesis after menopause.

The downstream consequences are multiple:

Bone. Eriksson et al. 2018 demonstrated through Mendelian randomization in 11,097 men that a 1 pg/mL genetically lower estradiol is associated with a 0.048 SD lower lumbar spine BMD — a gradient that, across the CC vs AA estradiol difference, translates to meaningful bone density differences relevant to fracture risk.

Endometrial cancer. The Thompson et al. 2016 Mendelian randomization established estradiol as causal for endometrial cancer. CC carriers' lower systemic estradiol corresponds to lower endometrial stimulation — a protective direction for endometrial cancer risk.

Mood. Ancelin et al. 2020 found that lower-estradiol CYP19A1 genotypes increased incident late-life depression risk in postmenopausal women without prior depression, consistent with estrogen's role in modulating serotonergic neurotransmitter systems.

Aromatase inhibitor therapy. CC carriers start with already-low peripheral estradiol. During letrozole or anastrozole therapy, further suppression may be extreme, potentially producing more severe symptoms of estrogen deficiency (hot flashes, joint pain, vaginal atrophy) without proportionally greater efficacy against tumor tissue.

In men. CYP19A1 variants account for 5–10% differences in circulating estradiol in men (Travis et al. 2009). CC male carriers may have lower estradiol relative to testosterone, affecting bone density, insulin sensitivity, and mood.